{"preliminary_commentary":{"by_channel":{"x_thread":105,"youtube":70,"podcast":40,"x_video":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05374512\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TROPION-Breast02","nct_id":"NCT05374512","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tropion-breast02-nct05374512. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Arm 1: Dato-DXd","label":"Dato-DXd","type":"EXPERIMENTAL"},{"description":"Arm 2:\n\nIf no prior taxane, or prior taxane in the (neo)adjuvant setting and DFI \\> 12 months, paclitaxel or nab-paclitaxel\n\nIf prior taxane and DFI ≤ 12 months: capecitabine, carboplatin, or eribulin.","label":"Investigator's Choice of Chemotherapy (ICC)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":644,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Dato-DXd","otherNames":["Datopotamab deruxtecan (Dato-DXd, DS-1062a)"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Eribulin mesylate","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"AstraZeneca","official_title":"A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-08-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months)"},{"measure":"Overall Survival (OS)","timeFrame":"From randomisation until the date of death due to any cause (approximately 42 months)"}],"references":[{"citation":"Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, Traina TA, Vukovic P, Mapiye D, Maxwell MJ, Schmid P, Cortes J. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023 Nov;19(35):2349-2359. doi: 10.2217/fon-2023-0228. Epub 2023 Aug 1.","pmid":"37526149","type":"DERIVED"}],"start_date":{"date":"2022-05-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","url":"https://clinicaltrials.gov/study/NCT05374512"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tropion-breast02-nct05374512"}